Marital Status and Survival in Osteosarcoma Patients: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

Abstract

Background: As the most malignant bone tumor globally, osteosarcoma has drawn increased attention. However, no studies have focused on the association between marital status and survival rate. The objectives of this study were to determine the association between marital and survival rate of osteosarcoma patients based on the SEER database. Material/Methods: We enrolled a total of 2725 osteosarcoma patients between 1973 and 2015, including 1184 married, 154 divorced/separated, 136 widowed, and 1251 never-married patients. Survival rate was determined based on the Kaplan-Meier method in different marital subgroups. Multivariate Cox regression analysis was performed to explore independent prognostic factors. Results: The 5-year overall survival (OS) and cancer-specific survival (CSS) rates of the married, separated/divorced, widowed, and never-married subjects were 45.93%, 41.39%, 19.08%, and 57.21% (OS), and 49.97%, 45.85%, 22.14%, and 60.69% (CSS), respectively. The survival outcome among subgroups exhibited a clear difference, with a log-rank test p-value <0.0001. Multivariate Cox regression showed that widowhood served as the independent prognostic factor for decreased OS rather than marriage (HR, 1.246; 95% CI, 1.011-1.536; p-value=0.039) and CSS (HR, 1.34; 95% CI, 1.07-1.68; p-value=0.01). Moreover, the OS and CSS in widowed patients were lower. Additionally, based on the propensity score matching (PSM) method, the prognosis of married patients was better than that of unmarried subjects. Conclusions: Marital status was correlated with the survival rate, meaning that married patients had higher survival than widowed subjects, who had worse prognoses of osteosarcoma.

microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis

“…Although not as prevalent as many other malignancies, OS represents the foremost primary bone cancer with the vast majority of cases seen among younger populations [1]. In addition, the 5-year survival rate worldwide has failed to improve for decades, remaining between 40 and 70% [3][4][5]. This can be partly attributed to the emergence of chemotherapeutic resistance in the treatment of OS [37,38].…”

“…The incidence of OS is estimated as '4' for the 0-14 years age range and '5' for 15-19 years age range per million people worldwide [3]. Moreover, the 5-year survival rate worldwide for OS remains to be largely appalling, with studies estimating a survival rate between 40 and 70% [3,4], a statistic which has failed to improve for decades [5]. Young age, first primary tumor, localized stage, low grade, and surgical treatment are factors that have all been positively linked with overall survival in OS [6].…”

Analysis and construction of a competitive endogenous RNA regulatory network of baicalin-induced apoptosis in human osteosarcoma cells

“…Osteosarcoma (OS) is the most common primary bone tumor with high mortality and poor prognosis [1,2] . Although neoadjuvant and postsurgery chemotherapy have improved in recent years, little has changed for patients with metastatic disease, and their long-term survival rate remains at 25-30% [3] . Therefore, there is a great need to explore new diagnostic and treatment strategies to reduce recurrence and improve the survival rate.…”

Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma

“…It has a high degree of malignancy and is prone to recurrence and metastasis (Harrison et al, 2018). Although surgery combined with chemotherapy has significantly improved the survival rate of patients with osteosarcoma, the long-term survival rate of patients with metastatic osteosarcoma is still only 15-20% (Qiu et al, 2019). Researchers have tried various methods to improve the efficiency of chemotherapy, including immunotherapy, targeted therapy, and other new treatment methods.…”